The content on this site is intended for healthcare professionals only
Dr. Hope Rugo shares her experience on the recommended treatment approach for ER-positive, HER2- breast cancer patients. She comments on what is the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumor.
She also provides interesting comments on the use of criteria like tumor grade and size to select the patients for adjuvant chemotherapy as well as the usage of IHC markers such hormone receptors ER-positive, PR and Growth Factor Receptor HER2 to identify patients for chemotherapy.
Finally, she speaks about tools such Adjuvant! Online and Predict and debates if these tools could be used to select luminal breast cancer patients confidently for adjuvant chemotherapy.
This programme has been supported by sponsorship from Genomic Health.
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma
Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Myeloma treatment and prognosis
Interpreting the results of a clinical trial
Looking at radioiodine and other radio-labelled metabolites for thyroid cancers
Early breast cancer: Treatment pattern
